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Background: Anti-integrin therapy is a new frontline strategy in the treatment of
inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently
being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis
(UC) in several phase III trials. Mechanistically, etrolizumab is known to block β7 integrin
ligand binding and reduces intestinal trafficking of β7-expressing cells. Etrolizumab
blocks β7 integrin ligand binding and reduces β7-positive lymphocyte migration and
retention in the inflamed gut mucosa, but the exact mechanisms by which this inhibition
occurs are not fully understood.
Methods: Cellular effects of etrolizumab or etrolizumab surrogate antibody
(etrolizumab-s) were investigated in cell culture models and analyzed by flow
cytometry, fluorescence microscopy, ImageStream R©, stimulated emission depletion
(STED) microscopy and functional dynamic in vitro adhesion assays. Moreover, effects
on α4β7 integrin were compared with the pharmacodynamically similar antibody
vedolizumab.
Results: As demonstrated by several different approaches, etrolizumab and
etrolizumab-s treatment led to internalization of β7 integrin. This resulted in impaired
dynamic adhesion to MAdCAM-1. Internalized β7 integrin localized in endosomes and
re-expression of β7 was dependent on de novo protein synthesis. In vitro etrolizumab
treatment did not lead to cellular activation or cytokine secretion and did not induce
cytotoxicity. Internalization of α4β7 integrin was increased with etrolizumab compared
with vedolizumab.
Discussion: Our data suggest that etrolizumab does not elicit secondary effector
functions on the single cell level. Integrin internalization may be an important mechanism
of action of etrolizumab, which might explain some but not all immunological effects
observed with etrolizumab.
Keywords: etrolizumab, inflammatory bowel diseases, internalization, STED microscopy, adhesion
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INTRODUCTION
Inflammatory bowel diseases (IBD), such as Crohn’s disease
(CD) and ulcerative colitis (UC) are marked by intestinal
immune cell infiltration leading to pro-inflammatory signaling
and tissue destruction (Strober et al., 2007; Kaser et al.,
2010; Neurath, 2014). Such cell accumulation in the gut is
controlled by cell trafficking processes including gut homing
and intestinal retention (Habtezion et al., 2016; Zundler and
Neurath, 2017). Adhesion of lymphocytes dependent on activated
α4β7 integrin to mucosal vascular addressin cell adhesion
molecule (MAdCAM)-1 expressed on high-endothelial venules
in the gut has been identified as an important mechanism of
gut homing (Berlin et al., 1993; Zundler et al., 2017a). The
translational potential of this mechanism has been impressively
demonstrated by the successful clinical implementation of
inhibiting the α4β7 integrin by the monoclonal antibody
vedolizumab as a therapeutic strategy in IBD (Feagan et al.,
2013; Sandborn et al., 2013). In addition to α4, the β7
integrin monomer also pairs with αE to form the αEβ7
heterodimer, which has been shown to control epithelial
retention of homed lymphocytes in intestinal inflammation
(Cepek et al., 1994). The anti-β7 antibody etrolizumab is
currently being investigated in several phase III trials in IBD
patients and blocks both α4β7-mediated gut homing as well as
αEβ7-controlled retention (Vermeire et al., 2014; Zundler et al.,
2017c).
While these mechanisms have been proposed by cell
trafficking studies (Zundler et al., 2017c), the molecular
mechanisms responsible for the effect of etrolizumab
have so far not been described. Here, we addressed the
hypothesis derived from previous studies with vedolizumab
(Wyant et al., 2013) that one mechanism of action of
etrolizumab might be internalization of β7 integrin leading
to unavailability of the integrin on the cell surface. We
show with complementary techniques including molecular
microscopy with stimulated emission depletion (STED)
imaging and ImageStream R© analyses that etrolizumab leads to
internalization of α4β7 integrin, that this functionally impairs
β7-dependent adhesion to MAdCAM-1, and that internalization
of α4β7 integrin is higher with etrolizumab compared with
vedolizumab.
MATERIALS AND METHODS
Patients With IBD
Peripheral blood was collected from patients with CD (n = 53)
and UC (n = 44) following prior informed written consent at the
Outpatient Department of the Medical Clinic 1 of the University
Hospital Erlangen. Control blood was obtained from healthy
donors (n = 27). Clinical data of blood donors are summarized in
Table 1. Blood collection was approved by the Ethics committee
of the Friedrich-Alexander University Erlangen-Nuremberg. For
some experiments, peripheral blood samples were collected from
an anonymous internal Genentech blood donor program of
healthy volunteers.
Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated by
standard density gradient centrifugation with either Lymphocyte
Separation Buffer (Anprotec) or Ficoll Paque (GE). Where
indicated, CD4+ T cells were purified from PBMCs with CD4
microbeads (Miltenyi).
Etrolizumab Surrogate Antibody
(Etrolizumab-s) Internalization
For assessment of etrolizumab-s internalization, PBMCs were
treated with 10 µg/mL of the etrolizumab surrogate rat
antibody FIB504 (Genentech) in phosphate buffered saline
(PBS) or in RPMI 1640 medium (Thermo Fisher) with 1%
penicillin/streptomycin (Biochrom) and 10% FCS (Pan Biotech)
at 4◦C and/or 37◦C for 24 h. Etrolizumab-s is the parent
antibody of etrolizumab (Stefanich et al., 2011). For some
experiments, etrolizumab-s was labeled with AlexaFluor (AF) 647
with an AF647 labeling kit (Thermo Fisher) according to the
manufacturer’s instructions.
Acid wash was performed with a solution of 0,5M NaCl +
0,2M acetic acid as previously described (Wyant et al., 2013).
Assessment of Etrolizumab
Internalization With ImageStream R©
Peripheral blood mononuclear cells were treated with
AF488-labeled etrolizumab (10 µg/mL) for 24 h at 37 or
4◦C. Cells were washed and stained with CD4 and CD45RA,
and subsequently with or without a quenching anti-AF488
antibody (addition of 25 µg to cell pellet on ice for 1 h, Thermo
Fisher Scientific). Surface and intracellular fluorescence signals
were recorded using the ImageStream R©X Mark II Imaging Flow
Cytometer (MilliporeSigma).
Flow Cytometry
The following antibodies were used for cell staining according to
standard flow cytometry protocols: CD4 (VIT4, VioBlue/FITC,
Miltenyi; RPA-T4, PE/V450, BD Biosciences), CD8 (RPA-T8,
PE-Cy7, BD Biosciences), CD45RA (HI100, V500/APC/BV510,
BD Biosciences/Biolegend), CD19 (SJ25C1, APC-Cy7, BD
Biosciences), IgD (IA6-2, V450, BD Biosciences), CD25 (BC96,
BV510, Biolegend), CD69 (FN50, APC/Cy7, Biolegend), CD103
(αE integrin) (Ber-ACT8, FITC/APC, BD Biosciences), IFN-γ
(B27, PE/Cy7, Biolegend), IL-4 (8D4-8, AF488, Biolegend), IL-
17A (BL168, PE, Biolegend), IL-9 (MH9A4, AF647, Biolegend),
CD49d (α4) (9F10, FITC/APC, BD Biosciences), 7AAD (BD
Biosciences). Additionally, etrolizumab, the anti-β7 integrin
antibody FIB504 and the anti-α4β7 integrin antibody Act-1 (all
Genentech) labeled with AF647 (AF647 labeling kit, Thermo
Fisher) and etrolizumab and the anti-β7 integrin antibody 9D8
(Genentech) labeled with AF488 (AF488 labeling kit, Thermo
Fisher) were used.
Where applicable, cells were fixed and permeabilized with the
Foxp3 fixation and permeabilization kit (Thermo Fisher).
For analysis of cellular activation (Wyant et al., 2013)
upon etrolizumab-s treatment, cells were treated with 1 µg/mL
etrolizumab-s for 6 h. Untreated PBMCs cultured for 6 h were
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TABLE 1 | Patient characteristics.
CON CD UC
Number 27 53 44
Age [years] (Mean +/− SEM) 26 +/− 1 37 +/− 2 41 +/− 2
Female [%] 63 41 41
HBI (Mean +/− SEM) 4.0 +/− 0.4
PMS (Mean +/− SEM) 1.7 +/− 0.3
Concomitant therapy [%] Immunosuppressants 11.3 4.6
Steroids 1.9 0
Mesalazin 0 6.8
Vedolizumab 0 0
Anti-TNF antibodies 86.8 88.6
Localization [%] L1: 17.0 E1: 18.6
L2: 11.3 E2: 32.6
L3: 41.5 E3: 48.8
L4: 0
L4+: 30.2
HBI, Harvey-Bradshaw Index; PMS, Partial Mayo Score.
used as negative control, while PBMCs treated with 50 ng/mL
PMA (Sigma) and 1 µM ionomycin (Cayman) for 6 h served as
positive control. After 2 h of culture, all cells were treated with
10 ng/µL Brefeldin A (Applichem) for the remaining 4 h.
For the analysis of β7 integrin re-expression, baseline
expression of β7 was determined in PBMCs. Subsequently, these
PBMCs were cultured in the presence of etrolizumab-s at 37◦C
for 24 h. Next, cells were harvested, washed and then re-seeded
in cell culture plates for a further 96 h in the presence or absence
of Brefeldin A. The time course of β7 integrin re-expression was
determined by flow cytometric analysis of aliquots cells harvested
at 24, 48, 72, and 120 h from baseline.
Flow cytometry was performed on MACSQuant X Analyzer
(Miltenyi) and BD FACSCantoTM II (BD Biosciences)
instruments. Data were analyzed with BD FACSDiva Software
v8.0. and FlowJo v7.6.5 and v10.1.
Comparison of Etrolizumab- and
Vedolizumab-Induced α4β7
Internalization
Peripheral blood mononuclear cells were pre-incubated
with saturating concentrations of unlabeled etrolizumab and
vedolizumab at 4◦C for 2 h. Cells were then washed and
incubated at 4 or 37◦C for 24 h prior to a subsequent wash
and staining with the non-competing anti-β7 monoclonocal
antibody 9D8-AF488. Surface β7 expression was assessed by flow
cytometry in subsets of B and T lymphocytes.
Dynamic in vitro Adhesion Assay
Peripheral blood mononuclear cells were cultured for 24 h
at 37◦C in the presence or absence of etrolizumab-s. Next,
cells were labeled with carboxyfluorescein succinimidyl ester
(CFSE; Life Technologies). Suspensions of 1.5 million cells/mL
in adhesion buffer (pH 7.4, 150 mM NaCl, 10 mM HEPES,
1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2) were prepared and
etrolizumab-s was added or not to aliquots of so far untreated
cells. Capillaries for dynamic in vitro adhesion assays were
prepared as previously described (Binder et al., 2018). In brief,
miniature borosilicate capillaries (Vitrocom) were coated with
5 µg/mL rhMAdCAM-1-Fc-chimera (R&D Systems) in 150 mM
NaCl with 10 mM HEPES for 1 h at 37◦C. Next, unspecific
binding sites were blocked with 5% bovine serum albumine (BSA)
in phosphate buffered saline (PBS) for 1 h at 37◦C.
Perfusion was performed with a peristaltic pump (Shenchen
LabV3) at a flow rate of 10 µL/min. Dynamic adhesion was
analyzed with time-lapse confocal microscopy (Leica SP8) over
3 min and analyzes with ImageJ (NIH) as previously described
(Binder et al., 2018).
Immunofluorescence
Peripheral blood mononuclear cells were treated with
AF647-labeled etrolizumab-s for 24 h at 37 or 4◦C. In some
experiments, cells were permeabilized with 0.1 % Triton X (Roth)
after etrolizumab-s incubation and additionally stained with
LAMP-1 (H4A3, AF488, Biolegend) or EEA (5632C2, AF488,
Novus Bio) to visualize lysosomes and endosomes, respectively.
Subsequently, cells were counterstained with Hoechst dye,
suspended in Mowiol (Roth) and covered on microscopy
slides. Analyses were performed with fluorescence microscopy
(Leica DM6000B). Surface and intracellular fluorescence signals
were quantified with ImageJ (NIH) by determining the mean
fluorescence intensity (MFI) of regions of interest defined around
or in projection to the nuclei, respectively.
STED-Microscopy
To increase the number of β7 integrin-expressing cells, PBMCs
were stimulated with anti-CD3 (OKT3, eBioscience) and
anti-CD28 antibodies (BE0248, inVivoMab) and additionally
treated with 20 ng/mL TGF-β for 72 h as previously described
(Zundler et al., 2017c).
Subsequently, such cells were treated with a mouse anti-
human β7 antibody (473207, R&D systems) or with or without
Frontiers in Pharmacology | www.frontiersin.org 3 February 2019 | Volume 10 | Article 39
fphar-10-00039 January 30, 2019 Time: 17:58 # 4
Lichnog et al. Mechanisms of Etrolizumab
etrolizumab-s at 37 or 4◦C for 24 h. Where indicated, cells
treated at 37◦C were additionally permeabilized with 0.1%
Triton X. Then, secondary staining was performed with goat
anti-mouse antibodies and goat anti-rat antibodies labeled with
the STED microscopy dye Star 580 (excitation: 594 nm pulsed
laser, emission: 605–625 nm) or Star 635P, respectively (both
Abberior, excitation: 640 nm pulsed laser, emission: 650–720 nm).
Cell suspensions in Mowiol were covered on microscopy slides
and analyzed with a STED microscope (Abberior 3D STED
2-Channel Super Resolution Microscope) equipped with a 100×
Oil immersion lens (NA: 1.44). Stimulated emission depletion
was performed at 775 nm with a pulsed laser. The power of the
STED laser was set to 625 mW.
Antibody-Dependent Cytotoxicity
(ADCC) Assay With PBMCs
Antibody-dependent cytotoxicity assays were carried out using
PBMCs from healthy donors as effector cells and the human
lymphoma cell line WIL2-S (ATCC) as target cells. Target cells
(4 × 104) in 50 µL assay medium (RPMI-1640 with 1% BSA
and 100 U/mL penicillin/streptomycin) were seeded in each well
of a 96-well, round-bottom plate. Serial fourfold dilutions (1000
to 0.0038 ng/mL) of etrolizumab and the anti-CD20 antibody
rituximab as a positive control (50 µL/well) were added to
the plates containing the target cells, followed by incubation
at 37◦C for 30 min to allow opsonization. Subsequently, 106
PBMC effector cells in 100 µL of assay medium were added to
each well and the plates were incubated for an additional 4 h.
After centrifugation, the supernatants were assayed for lactate
dehydrogenase (LDH) activity using a Cytotoxicity Detection
Kit (Roche Diagnostics). Cell lysis was quantified through
absorbance at 490 nm using a microplate reader. Absorbance
of wells containing only the target cells served as Low Control
and wells containing target cells lysed with Triton-X100 as High
Control. Antibody-independent cellular cytotoxicity (AICC) was
measured in wells containing target and effector cells without the
addition of antibody. The extent of specific ADCC was calculated
as follows:
% ADCC = 100 × (A490nm
(
High Control
)
− A490nm
(
Low Control
)
)/(A490nm
(
Sample
)
− A490nm (AICC))
The mean ADCC values from duplicates were plotted against the
antibody concentration, and the EC50 values were generated by
fitting the data to a four-parameter equation with SoftMax Pro.
Complement-Dependent Cytotoxicity
(CDC) Assay
The CDC assays were carried out using WIL2-S cells as
target cells and complement derived from human serum
(Quidel Corporation). Etrolizumab and the anti-CD20 antibody
rituximab were serially diluted in assay medium (RPMI-1640
supplemented with 20 mM HEPES pH 7.2, 0.1% BSA, and
0.1 mg/mL gentamicin), and distributed into a 96-well tissue
culture plate (Costar; Corning Inc.). Following the addition of
human serum complement (diluted 1:3 in assay medium) and the
target cells (105 cells/well), the plate was incubated 12 h at 37◦C.
After the incubation, AlamarBlue was added at 50 µL/well and
the plate was incubated for an additional 15–18 h. The CDC of
the test antibody was quantified through absorbance at 530 nm
excitation with 590 nm emission on a fluorescence plate reader
(SpectraMax GeminiXS, Molecular Devices). The EC50 values
were generated by fitting the data to a four-parameter equation
(SoftMax Pro).
Induction of Pro-inflammatory Cytokine
Production
Etrolizumab was evaluated in vitro both as a single agent
and in the presence of a sub-stimulatory concentration of
anti-human CD3 (4 ng/ml) for induction of pro-inflammatory
cytokine/chemokine production in purified human PBMCs.
PBMCs were assayed in 96-well microtiter plates (either
with or without anti-CD3 coating) with trastuzumab, mouse
IgG1, or etrolizumab, in solution phase. Positive control wells
were coated with both anti-CD3 (4 ng/ml) and anti-CD28
(100 ng/ml), whereas negative control wells remained uncoated.
Duplicate wells without anti-CD3 were also assayed, to
determine the capability of the solution-phase mAbs to
stimulate cytokine/chemokine production in PBMC without a
costimulatory signal. Each well contained 4 × 105 PBMC in
100 µL medium and plates were incubated at 37◦C. Supernatants
were collected following 24 and 48 h of culture and assayed by
Luminex assays (Luminex Corp.) for cytokine and chemokine
concentrations.
Statistics
Unless otherwise stated, data are displayed as mean with error
bars representing the standard error of the mean. Statistical
comparisons were performed with Graph Pad Prism software
(Graph Pad Software) applying one- or two-way ANOVA as
applicable. Post hoc testing was done with Newman-Keuls or
Bonferroni tests, respectively. Levels of significance are indicated
by asterisks (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
RESULTS
β7 Integrin Translocates From the Cell
Surface to the Inside of the Cell Upon
in vitro Treatment of Lymphocytes With
Etrolizumab-s
To assess whether β7 integrin is internalized upon etrolizumab
treatment, we isolated PBMCs from the peripheral blood of
healthy controls and IBD patients and incubated these cells with
or without etrolizumab-s in vitro. This was performed at 37◦C to
allow internalization or at 4◦C to prevent internalization (Wyant
et al., 2013). After 24 h, cells were stained for flow cytometry
with an antibody panel including the anti-β7 antibody 9D8 which
recognizes β7 in the presence of etrolizumab-s through binding to
a different epitope (Stefanich et al., 2011). At 4◦C, as expected due
to the absence of internalization, no difference in the abundance
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of CD4+9D8+ T cells could be observed between samples treated
with or without etrolizumab-s (Figure 1A). At 37◦C, however,
the proportion of CD4+ T cells staining positive for 9D8 was
significantly lower after etrolizumab-s treatment compared with
no treatment in control donors as well as IBD patients with CD
or UC. This suggested that the β7 integrin was reduced on the cell
surface following incubation with etrolizumab-s.
To investigate the fate of β7 after such treatment, we
performed an additional series of experiments, in which PBMCs
were incubated with AF647-labeled etrolizumab-s and stained
for flow cytometry after 24 h. We observed that the proportion
of etrolizumab-s+9D8− CD4 T cells was significantly higher
after incubation at 37◦C than at 4◦C (Figure 1B). Therefore,
we concluded that the fluorescence signal of etrolizumab-s
must originate from the inside of the cells, since the 9D8
antibody was only able to bind surface-expressed β7 integrin.
This was confirmed by another approach, in which we incubated
PBMCs with AF647-labeled etrolizumab-s at 4 and 37◦C for
24 h and applied an acid wash procedure afterwards to
remove surface-bound antibody. Unsurprisingly, the substantial
proportion of etrolizumab-s+ cells that could be observed
without acid wash treatment at 4◦C was almost completely
lost, when acid wash was applied (Figure 1C). In contrast, a
considerable amount of etrolizumab-s+ cells was observed at
37◦C even when acid wash was performed, which similarly
argued for an intracellular origin of the fluorescence signal.
Thus, taken together, these results supported the conclusion that
etrolizumab-s leads to internalization of β7 integrin.
β7 Integrin Is Internalized Following
Treatment of Lymphocytes With
Etrolizumab
We therefore aimed to complementarily explore the
internalization process with fluorescence microscopy.
Accordingly, we treated PBMCs from the peripheral blood of
controls and IBD patients with AF647-labeled etrolizumab-s at 4
and 37◦C for 24 h. After counterstaining with Hoechst, cells were
evaluated by fluorescence microscopy. Following incubation at
4◦C, we observed a halo of etrolizumab-s fluorescence signal
around the cell membrane in a portion of cells consistent with
β7 expression on the cell surface (Figure 2A). In contrast, the
signal observed in cells treated at 37◦C was shifted to the inside
of the cells. When quantifying the fluorescence signal in the
latter compared with the former location by measuring the MFI
for AF647, we found a highly significant difference in the ratio
of surface and intracellular fluorescence intensity. Consistent
with the flow cytometry results, these immunofluorescence
images provided further evidence of β7 internalization after
etrolizumab-s binding.
Subsequently, we explored whether these observations with
etrolizumab-s also applied to the humanized therapeutic
antibody etrolizumab. In an approach combining flow cytometry
with fluorescence microscopy we analyzed internalization of β7
integrin following treatment with AF488-labeled etrolizumab at
4 and 37◦C for 24 h with and without additional anti-AF488
quench (Figure 2B). When incubated at 4◦C, as expected,
superficial AF488 signal could be observed without, but not with
quench procedure. At 37◦C, however, microscopy demonstrated
only minimal superficial AF488 staining that was removed by the
quench procedure, but substantial intracellular signal that was
not affected by quenching of AF488. Consistently, flow cytometry
demonstrated AF488+ cells without and with quench at 37◦C.
Additionally, we performed dual staining with AF647-labeled
etrolizumab-s and the lysosome marker LAMP-1 or the
endosome marker EEA to assess the intracellular location of
etrolizumab-s after internalization (Figure 2C). At 37◦C, but
not at 4◦C co-localization of both EEA-1 and LAMP-1 with
etrolizumab-s could be observed suggesting internalization of
the antigen-antibody complex into early endosomes and late
endosomes/lysosomes, respectively.
To evaluate the internalization of β7 in even greater detail
and on single-molecule level, we made use of STED microscopy,
an innovative technology recently introduced to overcome the
resolution limitations of conventional microscopic techniques
(Blom and Widengren, 2017). Initially, we assessed the expression
of β7 integrin induced by TGF-β on PBMCs from IBD
patients and controls. Interestingly, β7 expression was not
homogenously distributed around the cells, but confined to
certain spots (Figure 3A). Subsequently, cells were treated
with etrolizumab-s at 4 and 37◦C for 24 h and secondary
staining with Star635P-labeled anti-rat antibodies was performed.
After treatment at 4◦C, as anticipated, we observed a fraction
of cells with a positive signal, which had a “halo” location
consistent with cell surface expression of β7 integrin (Figure 3B).
However, no such signal could be observed on cells treated
at 37◦C, presumably due to internalization of β7 and, thus,
unavailability of etrolizumab-s on the cell surface for secondary
staining. To directly demonstrate internalization, we additionally
permeabilized cells with Triton-X prior to addition of the
secondary antibody. Indeed, this treatment led to detection of a
positive signal in projection to the nucleus or directly adjacent,
therefore indicating internalized β7 integrin.
Etrolizumab-Driven α4β7 Integrin
Internalization Functionally Leads to
Decreased Dynamic Adhesion to
MAdCAM-1
Next, we sought to determine whether internalization of β7
following etrolizumab treatment equally affects internalization of
the β7 integrin monomer paired with α4 or αE. As demonstrated
by flow cytometry, we observed a loss of α4β7 following
treatment with etrolizumab in vitro at 37◦C compared with
4◦C (Figure 4A), although the number of α4+ cells was not
substantially affected. Similarly, the abundance of αE remained
unchanged, although the MFI of αE+ cells significantly decreased
after treatment at 37◦C (Figure 4B). Together, these findings
suggested that etrolizumab predominantly induces monomer
internalization leading to absence of surface α4β7, and possibly
also partial co-internalization of αE.
To investigate what α4β7 internalization functionally means
for interaction with MAdCAM-1, we used a dynamic adhesion
assay to study integrin-addressin interactions under shear stress
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FIGURE 1 | β7 integrin translocates from the cell surface to the inside of the cell upon in vitro treatment of lymphocytes with etrolizumab-s. (A) Upper panels: Flow
cytometry of peripheral blood mononuclear cells (PBMCs) from patients with Crohn’s disease (CD), ulcerative colitis (UC), and control donors (CON) treated with
etrolizumab-s for 24 h at 4 and 37◦C. Left: Representative flow cytometry. The frequency of 9D8+ staining on CD4+ T cells is indicated. Right: Quantitative flow
cytometry showing surface expression of 9D8 at 37◦C relative to expression at 4◦C (n = 5 per group). Lower panels: Representative (left) and quantitative flow
cytometry (right) of cells cultured at 4 and 37◦C without etrolizumab-s treatment. (B) Flow cytometry of PBMCs from CD, UC, and CON donors treated with
AF-647-labeled etrolizumab-s. Left: Representative flow cytometry. The frequency of etrolizumab-s+9D8− cells among CD4+ T cells is indicated. Right: Quantitative
flow cytometry showing the proportion of these cells at 4◦C in relation to 37◦C (n = 5 per group). (C) Quantitative flow cytometry of PBMCs treated with
AF647-labeled etrolizumab-s at 4 or 37◦C and subsequently subjected to acid wash (left) or not (right). n = 5 per group; data are normalized to expression at 37◦C.
∗∗∗p < 0.001; ns – not significant.
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FIGURE 2 | β7 integrin is internalized by treatment of lymphocytes with etrolizumab(-s). (A) Left: Representative images showing localization of the fluorescence
signal of AF647-labeled etrolizumab-s after treatment of cells from CD, UC, and CON donors at 4 or 37◦C for 24 h. Scale bar: 3 µm. Right: Quantification of mean
fluorescence intensity (MFI) of AF647 signal in the cytosol relative to the membrane at 4 and 37◦C; n = 5 per group. ∗∗∗p < 0.001. (B) Assessment of etrolizumab
internalization with ImageStream R©. Representative flow cytometry and microscopy results after cell incubation with AF488-labeled etrolizumab at 4◦C (upper row) or
37◦C (lower row) and without (left panels) or with (right panels) quench procedure. BF, bright field. Data are representative for two independent experiments with a
total of eight samples. (C) Representative images showing localization of AF647 fluorescence signal of etrolizumab-s and AF488 fluorescence signal of EEA (left) and
LAMP-1 (right) after cell treatment with etrolizumab-s at 4 or 37◦C for 24 h. Scale bar = 3 µm. Images are representative for three independent experiments.
(Binder et al., 2018). PBMCs were isolated from the peripheral
blood of control donors and IBD patients and incubated with or
without etrolizumab-s at 37◦C for 24 h to induce internalization
of β7 integrin or not, respectively. Subsequently, treated cells
were extensively washed to remove any remaining antibody
from the cell suspension. Previously untreated cells were either
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FIGURE 3 | Assessment of etrolizumab-s internalization by STED microscopy. (A) Representative STED microscopy images showing localization and distribution of
β7 integrin on the surface of cells from CD, UC, and CON donors. Additionally, a negative control (NEG) without primary antibody staining is shown. Images are
representative for seven independent experiments. (B) Representative images showing etrolizumab-s localization on/in cells incubated with etrolizumab-s at 4◦C or
cells incubated with etrolizumab-s at 37◦C and additionally treated with or without Triton-X. Additionally, a negative control without primary antibody staining is
shown. Images are representative for five independent experiments.
left untreated or treated with etrolizumab-s directly prior to
perfusion through MAdCAM-1-coated ultrathin glass capillaries
in the presence of etrolizumab-s. Substantial adhesion could
be observed, when completely untreated cells were perfused.
However, when cells treated with etrolizumab-s for 24 h and cells
concomitantly treated with etrolizumab-s were used, dynamic
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FIGURE 4 | β7 internalization minimizes α4β7 expression on the cell surface. (A) Representative flow cytometry plot showing expression of α4β7 integrin after
treatment with etrolizumab at 4 and 37◦C. Percentages indicate α4+β7+ and total α4+ cells. (B) Upper panels: Representative flow cytometry plots showing
expression of αE integrin after treatment with etrolizumab at 4 and 37◦C. Lower panel: Quantification of β7 mean fluorescence intensity (MFI) of β7+ cells (n = 5).
∗∗p < 0.01.
adhesion was markedly and similarly reduced (Figure 5).
Thus, internalization of β7 integrin following incubation with
etrolizumab-s led to a decrease in dynamic adhesion to
MAdCAM-1 even when no etrolizumab-s was present during
perfusion and this effect was comparable to that observed with
concomitant treatment. These results indicated that β7 integrin
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FIGURE 5 | Internalization of β7 integrin functionally leads to decreased dynamic adhesion to MAdCAM-1. Dynamic adhesion assays with untreated PBMCs,
PBMCs pre-treated with etrolizumab-s for 24 h or treated with etrolizumab-s during the assay. Left panels: Representative overlays of three differentially colored
sequential images collected at the beginning or end of 3 min clips. White cells represent adhering cells. Right panels: Quantitative data normalized to untreated
PBMCs (CD n = 8, UC n = 5, and CON n = 5). ∗∗p < 0.01, ∗∗∗p < 0.001.
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FIGURE 6 | Cell surface expression of β7 integrin is restored after removal of etrolizumab-s. (A) Left panels: Representative flow cytometry showing β7 integrin
expression at baseline (day 0) and 24 (day 1), 48 (day 2), 72 (day 3) and 120 h (day 5) after treatment with etrolizumab-s for the first 24 h of the experiment. Right
panels: Quantitative flow cytometry of β7 surface expression over time relative to day 0 (n = 5–6 per group). (B) Left panels: Representative flow cytometry showing
β7 integrin expression at baseline (day 0), and 24 (day 1), 48 (day 2), 72 (day 3) and 120 h (day 5) after treatment with etrolizumab-s for the first 24 h of the experiment
and treatment with Brefeldin A from day 1 to day 5. Right panels: Quantitative flow cytometry of β7 surface expression over time relative to day 0 (n = 5–6 per group).
internalization induced by etrolizumab is functionally important
for the impairment of interactions with MAdCAM-1.
Cell Surface Expression of β7 Integrin Is
Restored After Removal of Etrolizumab-s
We then assessed whether β7 integrin is re-expressed on the
cell surface after treatment with etrolizumab-s. To analyze
this, PBMCs from the peripheral blood were incubated with
etrolizumab-s for 24 h and aliquots of the cells were used to
determine β7 integrin expression on CD4+ T cells with the 9D8
antibody (labeled with AF488) before and after treatment to
confirm downregulation of surface β7 expression (Figure 6A).
Subsequently, cells were washed to remove excess etrolizumab-s
and further cultured for additional 96 h. Cell surface expression
of β7 integrin was analyzed after 24, 48, and 96 h and was found
to gradually increase until almost reaching pre-treatment levels
after 4 days.
To address whether this was due to recycling of internalized
β7 integrin or resulting from de novo synthesis, we performed
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an additional series of experiments, in which etrolizumab-s
treatment was followed by application of Brefeldin A to inhibit
Golgi transport of freshly translated β7 protein. During such
incubation, surface β7 integrin expression persisted on the
levels observed directly after treatment with etrolizumab-s
(Figure 6B). Together, these results suggested that internalized
β7-etrolizumab-s aggregates are degraded and β7 expression on
the cell surface after removal of etrolizumab-s is restored due to
de novo-synthesis of β7 integrin.
Etrolizumab-s Does Not Elicit Agonistic
Activity
Since monoclonal therapeutic antibodies can potentially have
agonistic activity (Winkler et al., 1999), we addressed the
expression of activation markers following incubation with
etrolizumab-s for six and 24 h. Cells treated with PMA and
ionomycin served as positive, untreated cells as negative control.
As expected, stimulation with PMA/ionomycin caused a clear
upregulation of CD69 on CD4+ T cells after six and 24 h
(Figure 7A). In contrast, and in accordance with the literature
(Wyant et al., 2013), CD25 was only modestly upregulated after
six, but markedly increased after 24 h. No induction of CD69
or CD25 could be observed in untreated samples and, similarly,
the expression in etrolizumab-s-treated samples was unchanged.
These data indicated that binding of etrolizumab-s to β7 integrin
does not lead to cell activation.
In a next step, we investigated whether etrolizumab-s has a
direct effect on the expression of pro-inflammatory cytokines.
Cells were left untreated or treated with etrolizumab-s or
PMA/ionomycin for 2 h. Subsequently, Brefeldin A was added
for additional 4 h and the expression of cytokines was assessed by
flow cytometry. While increased expression of IFN-γ, IL-4, IL-9,
and IL-17A could be observed in PMA/ionomycin-treated CD4+
T cells (Figure 7B), only very low and comparable production
was found in untreated cells and etrolizumab-s-treated cells.
Additionally, we assessed the concentration of several
cytokines and chemokines in supernatants of PBMCs following
treatment with etrolizumab (Figure 8A and Supplementary
Figure S1). Consistently, cytokine and chemokine levels observed
after etrolizumab treatment were similar to negative controls.
As monoclonal antibodies may also induce antibody-
dependent cell-mediated cytotoxicity (ADCC) or complement-
dependent cytotoxicity (CDC), we performed ADCC and CDC
assays with etrolizumab using the human lymphoma cell line
WIL2-S. The anti-CD20 antibody rituximab served as positive
control. While substantial ADCC and CDC were observed with
rituximab, neither was observed with etrolizumab (Figure 8B).
Etrolizumab Is More Effective Than
Vedolizumab in Inducing β7
Internalization
The anti-α4β7 antibody vedolizumab and etrolizumab both target
the α4β7 integrin and internalization of α4β7 integrin in response
to vedolizumab incubation has previously been described (Wyant
et al., 2013). Therefore, we aimed to compare the efficacy of both
compounds in inducing β7 integrin internalization.
To this end, PBMCs were treated with vedolizumab or
etrolizumab at 4◦C and 37◦C and surface β7 expression was
analyzed in T and B cells. Consistent with our previous findings,
etrolizumab treatment led to a clear reduction of β7 on all
subsets studied (Figures 9A,B). Vedolizumab treatment also
led to a decrease in expression and fluorescence intensity of
surface β7, but this was clearly less marked than the decrease
seen after etrolizumab treatment. Importantly, vedolizumab
almost completely prevented binding of Act-1 (Supplementary
Figure S2) indicating full saturation of α4β7 integrin.
DISCUSSION
Anti-integrin therapy has successfully been established as a
new concept in the treatment of IBDs (Lobatón et al., 2014;
Zundler et al., 2017a). Mechanistically, it is believed that targeted
inhibition of the interaction of integrins with respective ligands
by monoclonal antibodies leads to impaired cell trafficking
and subsequent reduction of pro-inflammatory cell infiltration
in the gut (Habtezion et al., 2016; Zundler and Neurath,
2017). However, beyond such mechanisms on the tissue level
and regarding cell trafficking, the mode of action of these
anti-integrin agents on their integrin target and the cellular
consequences of antibody targeting are only partly understood.
Here, we investigated the fate of β7 integrin upon binding of
both etrolizumab-s and etrolizumab, which is currently being
investigated in phase III studies in IBD. Etrolizumab is directly
derived from the etrolizumab surrogate rat antibody FIB504
(Andrew et al., 1994) that was used in a part of the studies
and has comparable binding properties (Stefanich et al., 2011).
Consistently, the effects observed with etrolizumab-s paralleled
the effects of etrolizumab, the humanized antibody.
On a single cell level, antibody binding to a target molecule
may induce several cellular effects such as induction or blockage
of cell activation and consecutive cytokine release. A prominent
example for this effect is the anti-CD28 antibody TGN1412,
which caused a cytokine storm with severe clinical consequences
in participants of a phase I study (Suntharalingam et al.,
2006). Increased cytokine secretion has also been observed in
patients treated with the anti-CD20 antibody rituximab (Winkler
et al., 1999), particularly in individuals with high peripheral cell
numbers, and following treatment with the anti-CD3 antibody
OKT3 (Gaston et al., 1991). Regarding etrolizumab, our in vitro
data demonstrate that it does not cause upregulation of cell
activation markers like CD25 and CD69, and that cytokine
secretion by CD4+ T cells is also unaffected. Thus, agonist
activity of etrolizumab on cell activation is highly unlikely. It
is important to mention that these observations do not exclude
effects of etrolizumab on cytokine expression on the tissue level as
suggested by the decline reported in previous studies (Vermeire
et al., 2014; Tew et al., 2016). This might be a secondary effect
due to altered cell trafficking and reduced numbers of pro-
inflammatory cells in the tissue.
Another potential mechanism mediated by therapeutic
antibodies is the induction of ADCC or CDC as observed
with the above mentioned antibodies rituximab and
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FIGURE 7 | Etrolizumab-s does not elicit agonistic activity and cytokine production. (A) Left panels: Representative flow cytometry showing expression of CD25
(upper panels) and CD69 (lower panels) after cell treatment with or without PMA/ionomycin and etrolizumab-s for 6 or 24 h. Right panels: Quantitative flow cytometry
(n = 11–26). (B) Left panels: Representative flow cytometry showing expression of pro-inflammatory cytokines after cell treatment with or without PMA/ionomycin
and etrolizumab-s for 6 h. Right panels: Quantitative flow cytometry (n = 21–23 per group). ∗∗∗p < 0.001; ns – not significant.
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FIGURE 8 | Etrolizumab does not elicit cytokine production and cytotoxicity. (A) Concentration of cytokines in supernatants of human PBMCs incubated with
different antibodies with or without stimulation with anti-CD3 after 24 and 48 h. n = 6, mean +/– SD. (B) Left panel: ADCC activity of different concentrations of
etrolizumab (rhuMAb Beta7) and rituximab in WIL2-S cells quantified as specified in Methods. Right panel: CDC assay with different concentrations of etrolizumab
and rituximab in WIL2-S cells as specified in Methods. Relative fluorescence units (RFU) indicate the number of viable cells. Data are representative for three
independent experiments.
OKT3 (Raasveld et al., 1993; Golay et al., 2002). Both effects
are mediated by the Fc fragment of the antibodies (Vidarsson
et al., 2014). Our data suggest that etrolizumab does not elicit
cytotoxicity via either mechanism. The observations reported
in preclinical models and clinical studies, where the numbers
of peripheral blood lymphocytes were stable or even increasing
(Stefanich et al., 2011; Vermeire et al., 2014) under treatment,
indicate that this is also not the case in vivo.
Internalization of the antibody-antigen complex into the cell
is frequently observed in response to antibody treatment (Harper
et al., 2013; de Goeij et al., 2014; Xu, 2015). We therefore
hypothesized that this might also be true for etrolizumab. Indeed,
our microscopic and flow cytometric data strongly support
the conclusion that this is case, since, upon treatment with
etrolizumab or etrolizumab-s, β7 could be detected intracellularly
and reduced presence of β7 integrin on the cell surface was
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FIGURE 9 | Comparison of β7 internalization after treatment with vedolizumab and etrolizumab in vitro. (A) Internalization of β7 on CD4+ T and CD19+ B cells from
the peripheral blood of human donors. Representative dot plots indicating the percentage of β7+ cells upon treatment with etrolizumab or vedolizumab at 4 or 37◦C
as indicated. (B) Quantification of β7+ internalization (decrease of surface β7 expression related to expression observed after treatment at 4◦C) in T and B cell
subsets treated with etrolizumab or vedolizumab as indicated. Memory cells were defined as CD45RA−. All analyses were performed on β7high cells (n = 5 donors).
ETZ, etrolizumab; VDZ, vedolizumab; n = 10. ∗∗∗p < 0.001.
observed. This was finally confirmed by molecular microscopy
using STED imaging, where β7 integrin vanished from the cell
surface after etrolizumab-s treatment, but could be detected
inside the cells after permeabilization. Thus, internalization
seems to be a common feature of integrin ligation by neutralizing
antibodies and even natural ligands. E.g., a similar mechanism
has been reported for the anti-α4β7 antibody vedolizumab
(Wyant et al., 2013) and the anti-rat α4 antibody TA2 (Leone
et al., 2003). Moreover, it has been shown that engagement
of α4β1 with its endothelial ligand vascular adhesion molecule
(VCAM)-1 leads to internalization of the addressin (Ricard et al.,
1998).
Using dynamic adhesion assays, we could additionally
demonstrate that β7 internalization upon etrolizumab-s
treatment has functional consequences and decreases adhesion
to MAdCAM-1. Thus, receptor internalization might in fact
explain the pre-clinical and clinical effects of etrolizumab
(Stefanich et al., 2011; Vermeire et al., 2014).
However, compared to the in vitro results, the in vivo
situation seems to be more complex. As demonstrated by
the recent phase II trial with etrolizumab in UC (Vermeire
et al., 2014), there was no apparent loss of β7 expression
on the cell surface relative to baseline. Our data show
that after removal of etrolizumab-s from cell cultures, β7
integrin is newly expressed within few days. Thus, surface-
expressed β7 in etrolizumab-treated patients might at least
partly result from de novo synthesis of the integrin, as it
is highly likely that internalization and re-expression occur
in parallel in vivo. In the light of recent studies suggesting
compensatory mechanisms in response to anti-integrin therapies
(Fuchs et al., 2017; Zundler et al., 2017b), it is also tempting to
speculate that anti-integrin antibody treatment might trigger a
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compensatory increase in de novo integrin expression. Moreover,
it has to be taken into account that anti-β7 treatment is
believed to lead to an increased number of target cells in the
peripheral blood due to impairment of gut homing (Vermeire
et al., 2014; Binder et al., 2018). Thus, in synopsis, in
addition to blockade, it is likely that internalization is one
of several mechanisms of actions of etrolizumab in vitro and
in vivo.
Our data are also in line with and a potential explanation
for the favorable safety profile observed with etrolizumab and
gut-specific anti-adhesion therapies in general so far (Lin et al.,
2015; Luthra et al., 2015), since they suggest the absence of
effector properties affecting key cellular functions other than β7
blockade (Liu et al., 2008).
In a final series of experiments, we compared the efficacy
of β7 internalization after treatment with vedolizumab and
etrolizumab in vitro. Our data indicate that etrolizumab is more
effective in this regard and, thus, suggest that these anti-integrin
antibodies do not only differ in regard to the overall mechanism
of action (Zundler et al., 2017c), but may also act differently on
a cellular level. E.g., it seems possible that different mechanisms
of endocytosis apply. Although functional short-term effects
on α4β7-dependent adhesion to MAdCAM-1 were similar for
both antibodies (Binder et al., 2018), differential internalization
properties might lead to differences in the efficacy of α4β7
blockade in the longer term.
Taken together, our data suggest that antibody-antigen
complex internalization may be an important mechanism of
action of etrolizumab and might help us better understand
the clinical effects and the safety profile of etrolizumab
in IBD.
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